CorAssist Cardiovascular - Innovative Solutions for heart failure with preserved ejection fraction (HFpEF)
CorAssist is pioneering the treatment of
heart failure with preserved ejection
fraction (HFpEF) patients
CorAssist Cardiovascular - Innovative Solutions for Heart Failure with Preserved Ejection Fraction (HFpEF)

Executive Staff

Yair Feld, Director

Dr. Feld is a co-founder of CorAssist and currently heads GeneGrafts, a startup company developing a gene therapy approach for the treatment of atrial fibrillation. Dr. Feld is also founder of Nephera and ProArc Medical and has over 15 years of experience in leading innovative research and development projects. Dr. Feld holds an MD and PhD in Physiology and Biophysics from the Technion – Israel Institute of Technology.

Giorgi Shtenberg, Clinical Research Manager

Dr. Shtenberg joined CorAssist in 2015, bringing with him multidisciplinary expertise in nanomaterials, semiconductors, microfluidics, photonics, and biological interfaces for biomedical applications. Dr. Shtenberg holds BSc and PhD in Biotechnology Engineering from the Technion – Israel Institute of Technology.